Atopic Dermatitis (Eczema) Treatment
Covered by Aetna in California

For mild-to-moderate eczema flares: triamcinolone acetonide 0.1% cream twice daily × 7–14 days for body (trunk, extremities); desonide 0.05% cream or lotion twice daily for face, eyelids, and skin folds; fragrance-free emollient (white petrolatum, CeraVe, Vanicream) applied liberally 2–3× daily as cornerstone maintenance therapy — moisturizers are an AAD strongly recommended first-line intervention

Tacrolimus 0.1% ointment (or 0.03% for children <16) twice daily for maintenance on face/neck — avoids steroid atrophy; pimecrolimus 1% cream for milder facial AD; crisaborole 2% ointment (Eucrisa) twice daily for mild-to-moderate AD — PDE4 inhibitor, steroid-free, useful for facial and intertriginous eczema in patients ≥3 months; for moderate-to-severe AD after documented topical failure, refer to dermatology for dupilumab (Dupixent) — must be prescribed by or in consultation with a dermatologist for Aetna PA; tralokinumab (Adbry) or lebrikizumab as alternatives per AAD 2024–2025 updated guidelines; wet-wrap therapy and bleach baths as adjunctive strategies per AAD conditional recommendations

Yes (topical agents) — generic triamcinolone 0.1% cream $4–$15; generic tacrolimus ointment $20–$60; pimecrolimus cream $30–$80 generic. Crisaborole (Eucrisa): covered with PA on Aetna CA; with insurance copay typically $30–$100/month. Dupilumab: covered with PA as specialty biologic; without insurance ~$3,600/month — Sanofi's patient assistance program and manufacturer copay card (as low as $0/month for eligible commercially insured patients) are available.

Per AAD 2024–2025 atopic dermatitis guidelines (updated), strong recommendations support topical corticosteroids, topical calcineurin inhibitors (tacrolimus, pimecrolimus), crisaborole, and dupilumab. Updated guidelines strongly recommend dupilumab, tralokinumab, abrocitinib, baricitinib, and upadacitinib for moderate-to-severe AD; emerging evidence supports tapinarof cream, roflumilast cream, lebrikizumab, and nemolizumab. AAD guidelines strongly recommend against systemic corticosteroids for AD due to the risk of disease rebound and long-term adverse effects. Staphylococcus aureus colonization of AD skin is near-universal in flares — bleach baths (0.005% bleach in bathwater, AAD protocol) reduce bacterial load and flare frequency.

Aetna CA covers dupilumab for moderate-to-severe atopic dermatitis but requires prior authorization from a dermatologist or allergist — not from a primary care or telehealth-only provider. A TDMD visit can document your AD severity, treatment history (topical corticosteroid and calcineurin inhibitor trials), and clinical rationale, and refer you to an in-person dermatologist who can submit the PA package. The PA criteria require ≥10% BSA involvement (or crucial body area involvement), plus documented inadequate response to both a high-potency topical corticosteroid AND a topical calcineurin inhibitor within the prior 180 days. California DMHC Independent Medical Review rights apply if denied.

Crisaborole is a steroid-free PDE4 inhibitor FDA-approved for mild-to-moderate AD in patients ≥3 months. It's useful for facial, eyelid, and skin-fold eczema where repeated steroid use raises skin atrophy concerns. Aetna CA covers it with PA under Policy 3199-E — the key clinical criteria are: age ≥3 months, and either sensitive skin area involvement OR inadequate response to a mid-to-high potency topical steroid, OR a contraindication to steroids. Initial approval is 3 months. Dr. Bhavsar will document the appropriate clinical criteria in the visit summary to support the PA submission.

Possibly, yes. Research from UCSF (JAMA Dermatology, 2021) and subsequent studies have linked wildfire smoke to eczema flares — PM2.5 and polycyclic aromatic hydrocarbons in wildfire smoke can penetrate compromised atopic skin and trigger inflammation. In California's fire season (typically July–November), patients with AD should monitor local air quality (AirNow.gov), keep prescription rescue topical steroids filled and available, apply emollients more frequently on low-humidity or smoky days, and limit outdoor activity when AQI exceeds 150. If smoke-related flares are recurring, Dr. Bhavsar can discuss adjusting your maintenance regimen seasonally.

Yes — bleach baths are an AAD conditionally recommended adjunctive strategy for atopic dermatitis. The AAD protocol: add 1 teaspoon of regular (not concentrated) household bleach per gallon of warm water; soak for 5–10 minutes 2–3 times per week. The dilute bleach concentration (approximately 0.005%) reduces S. aureus colonization on the skin surface, which is a major driver of AD flares. It should not be used on open, severely excoriated skin or near the eyes. Most patients report reduced itch and flare frequency with consistent bleach bathing. This is a no-cost intervention you can start immediately alongside prescription treatment.

Yes. Aetna commercial plans cover telehealth visits for Atopic Dermatitis (Eczema) in California. TeleDirectMD (Dr. Parth Bhavsar, MD, NPI: 1104323203) is an in-network telehealth provider with Aetna in California. Your standard Aetna telehealth copay applies — typically $10–$40 for most commercial plans. If clinically appropriate, your prescription is sent to your California pharmacy immediately after your visit.

Most Aetna commercial plans in California have telehealth copays of $10–$40. Often $0–$20 for employer plans. Your exact cost depends on your specific plan and whether your deductible has been met. Log into your Aetna member portal or call the member services number on your card to verify your telehealth copay before your eczema treatment visit. Self-pay is always available for a flat $49 if you prefer to skip insurance.

If your specific Aetna plan is not in-network with TeleDirectMD in California, or if your deductible has not yet been met, you can book as a self-pay patient for a flat $49 fee — same physician, same quality of care, no insurance needed. You may also be eligible to submit an out-of-network claim to Aetna for partial reimbursement depending on your plan's out-of-network benefit.

TeleDirectMD typically offers same-day and next-day video visits. Book at teledirectmd.com/book-online and select a time that works for you. Most patients are seen within a few hours of booking during business hours. Your eczema treatment symptoms are evaluated by Dr. Bhavsar, MD — not a nurse practitioner or PA — ensuring you receive a board-certified clinical assessment.

Yes. TeleDirectMD is operated by Dr. Parth Bhavsar, MD (NPI: 1104323203), a board-certified Family Medicine physician. TeleDirectMD is LegitScript certified, HIPAA compliant, and is contracted as an in-network telehealth provider with Aetna in California. Claims are billed using standard CPT codes (99213/99214) and submitted electronically to Aetna.

Yes. Telehealth visits with a licensed physician are qualified medical expenses eligible for FSA (Flexible Spending Account) and HSA (Health Savings Account) payment. If your Aetna plan applies your deductible first, your FSA or HSA card can be used to pay your portion. The $49 self-pay option is also FSA/HSA eligible.